Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Cardiovascular Diabetology
|
January 18, 2012
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Michael E Cobble, Robert Frederich
Therapeutic Innovation & Regulatory Science
|
October 7, 2023
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
Shuai Wang, Robert Frederich, James P Mancuso
The Journal of Laboratory and Clinical Medicine
|
March 29, 2002
Leptin in anorexia nervosa and bulimia nervosa: importance of assay technique and method of interpretation
Robert Frederich, Shousheng Hu, Nancy Raymond, et al.
BMC Endocrine Disorders
|
February 26, 2014
A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
Judith L White, Patricia Buchanan, Jia Li, et al.
Postgraduate Medicine
|
June 11, 2013
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials
William Cook, Brian Bryzinski, Jill Slater, et al.
Cardiovascular Diabetology
|
February 5, 2014
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
Nayyar Iqbal, Artist Parker, Robert Frederich, et al.
Diabetology & Metabolic Syndrome
|
July 26, 2012
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
Robert Frederich, Robert McNeill, Niklas Berglind, et al.
Diabetes & Vascular Disease Research
|
May 13, 2011
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
Priscilla L Hollander, Jia Li, Robert Frederich, et al.
Clinical Interventions in Aging
|
April 30, 2013
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
Chetan S Karyekar, Shoba Ravichandran, Elsie Allen, et al.
Clinical Pharmacology in Drug Development
|
April 25, 2018
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices
Ellen Q Wang, Anna Plotka, Joanne Salageanu, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Cardiovascular Diabetology
|
January 18, 2012
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Michael E Cobble, Robert Frederich
Therapeutic Innovation & Regulatory Science
|
October 7, 2023
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
Shuai Wang, Robert Frederich, James P Mancuso
The Journal of Laboratory and Clinical Medicine
|
March 29, 2002
Leptin in anorexia nervosa and bulimia nervosa: importance of assay technique and method of interpretation
Robert Frederich, Shousheng Hu, Nancy Raymond, et al.
BMC Endocrine Disorders
|
February 26, 2014
A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
Judith L White, Patricia Buchanan, Jia Li, et al.
Postgraduate Medicine
|
June 11, 2013
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials
William Cook, Brian Bryzinski, Jill Slater, et al.
Cardiovascular Diabetology
|
February 5, 2014
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
Nayyar Iqbal, Artist Parker, Robert Frederich, et al.
Diabetology & Metabolic Syndrome
|
July 26, 2012
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
Robert Frederich, Robert McNeill, Niklas Berglind, et al.
Diabetes & Vascular Disease Research
|
May 13, 2011
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
Priscilla L Hollander, Jia Li, Robert Frederich, et al.
Clinical Interventions in Aging
|
April 30, 2013
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
Chetan S Karyekar, Shoba Ravichandran, Elsie Allen, et al.
Clinical Pharmacology in Drug Development
|
April 25, 2018
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices
Ellen Q Wang, Anna Plotka, Joanne Salageanu, et al.
Page
of 4